Spit test could replace blood draws in tracking rare disease

This study aims to find new, easier-to-measure signs in the body that can help doctors understand organ damage and predict how well a treatment works for EGPA, a rare inflammatory disease. Researchers will collect and compare blood, saliva, and sputum samples from 90 patients with EGPA or severe asthma before and after they start a standard drug called mepolizumab. The main goal is to see if a simple saliva test can provide the same useful information as a blood test, making monitoring easier for patients.